Last updated: July 19, 2026
Sanofi-Aventis U.S. LLC v. Breckenridge Pharmaceutical, Inc. 3:15-cv-00289: Litigation Summary, Patent Issues, and Generic Entry Risk
Sanofi-Aventis U.S. LLC v. Breckenridge Pharmaceutical, Inc. (No. 3:15-cv-00289) is a U.S. Hatch-Waxman patent infringement dispute tied to a branded Sanofi product and a Breckenridge ANDA filing, with the core issues focused on whether Breckenridge’s proposed generic infringed asserted Sanofi patents and whether those patents were invalid or unenforceable. The case sits in the Paragraph IV framework that typically determines whether FDA approval and launch are blocked by court-driven exclusivity.
Key business read-through: You need to map (1) the asserted patent numbers, (2) the specific ANDA dosage form(s) and strength(s), (3) the outcome of each asserted claim, and (4) the resulting settlement or final judgment terms to assess remaining risk of immediate generic entry and the strength of Sanofi’s patent estate.
No patent numbers, asserted claims, judgment dates, settlement terms, or Orange Book-linked ANDA details are included in the input provided. Per operating constraints, no further litigation-specific conclusions can be produced.
What patents were asserted in Sanofi-Aventis v. Breckenridge 3:15-cv-00289?
The litigation synopsis depends on the complaint’s “asserted patent(s)” list and any amended infringement contentions. Those are not provided in the input.
Which patent numbers and claim groups were in play
A complete and accurate answer requires:
- the asserted U.S. patent numbers (and likely claim numbers),
- whether patents were asserted as method-of-use, composition/formulation, or formulation-manufacturing,
- which asserted patents remained after any claim narrowing.
How the court typically frames infringement and invalidity in this type of case
In Hatch-Waxman suits, the court’s live issues usually track:
- infringement of each asserted claim by the ANDA product,
- statutory invalidity defenses (anticipation/obviousness) and unenforceability defenses (inequitable conduct),
- case-specific claim construction outcomes.
Those specifics cannot be supplied without the actual docket filings or the complaint/Markman record.
What is the procedural timeline in 3:15-cv-00289?
A timeline requires docket events such as:
- complaint filing date,
- service date,
- answer and counterclaims,
- claim construction (Markman) hearing,
- summary judgment motion schedule,
- trial or settlement briefing,
- final judgment date or dismissal date.
The input provides only the case number and parties, not the procedural record.
Did the case result in a final judgment or a settlement?
The generic entry forecast turns on whether:
- the case ended in a merits decision (claim-by-claim invalidity/infringement),
- or ended in dismissal pursuant to settlement (often with an agreed launch date and/or covenant structure).
No disposition details are provided.
What does the case mean for FDA approval timing
Even where a case settles, the practical effect hinges on:
- whether the settlement triggered a consent to dismissal after the 30-month stay expired, or extended a de facto launch date,
- whether patents remaining in the Orange Book continued to block launch.
No Orange Book or settlement terms are included.
How strong is Sanofi’s patent estate in this Breckenridge dispute?
“Strength” in litigation is claim-specific and depends on:
- which asserted patents were found invalid or not infringed,
- whether the court construed key claim terms against the patentee,
- whether any patents survived dispositive motions.
Without asserted patent numbers and outcomes, no strength assessment can be generated.
Patent estate durability signals investors look for
The most decision-relevant indicators are:
- survival through claim construction and summary judgment,
- whether the court found invalidity for anticipation/obviousness,
- whether the case’s outcome aligned with claim scope breadth or narrow formulation parameters.
Those data points are absent.
Which FDA ANDA product was challenged in 3:15-cv-00289?
Hatch-Waxman suits are product- and strength-specific. Risk to Breckenridge, and to competitors considering launch, depends on:
- the ANDA drug (active ingredient),
- dosage form (tablet, capsule, injection, etc.),
- strength(s),
- whether the proposed generic used a particular formulation technique relevant to the asserted patents.
The input does not identify the active ingredient or dosage form.
Did Breckenridge file a Paragraph IV certification tied to the asserted Sanofi patents?
To evaluate entry risk, you must know:
- whether certifications were Paragraph IV as to each asserted patent,
- whether there were “section viii” notice elements that influenced timing,
- whether any later FDA approvals or amendments occurred.
The input provides no certifications or Orange Book mapping.
What generic entry risks exist for Breckenridge after this case?
Generic entry risk post-litigation depends on:
- whether any asserted patents were held valid/enforceable and infringed,
- whether the case was dismissed with a settlement that imposed launch limits,
- whether any additional, unasserted Orange Book patents still block launch.
No enforcement or settlement outcome is included.
Common settlement and launch constructs in Hatch-Waxman
A full analysis would typically cover:
- agreed launch dates,
- entry carve-outs by strength or formulation,
- sales conditions and injunction scope,
- covenants not to sue and dismissal scope.
No settlement document terms are in the input.
What settlements or covenants were imposed in Sanofi v. Breckenridge (3:15-cv-00289)?
Settlement analysis requires:
- settlement agreement date,
- dismissal language,
- whether there was a covenant not to sue for earlier launch,
- whether the parties stipulated to final judgment terms.
No settlement terms are provided.
How does the court’s decision affect exclusivity and design-around risk?
A design-around analysis is driven by the court’s reasoning:
- claim construction that narrows what “infringement” means,
- findings that certain features are not required (broad claims),
- findings that certain product attributes are mandatory (pinpointed infringement).
The input contains no decision record.
Potential design-around pathways that matter in practice
Generic entrants look for:
- alternate salts/polymorphs,
- alternate release profiles,
- alternate manufacturing methods,
- alternative dosing regimens (for method-of-use patents).
These are not anchored to any asserted claim language here.
Are there related cases in the same active ingredient patent family?
Sanofi and Breckenridge frequently face multi-patent, multi-case pressure in the same lifecycle. A complete map would include:
- co-pending lawsuits by other ANDA filers (other Paragraph IVs),
- related cases in the same district or parallel jurisdictions,
- whether other generics were enjoined based on the same patents.
No related-case index is included.
What is the Orange Book status of the asserted patents and products?
Orange Book status governs:
- listed patents and their expiration dates,
- patent expiration vs. regulatory exclusivity windows,
- whether the asserted patents are “listed” or “deleted” at the time of suit.
The input provides no Orange Book linkage.
Key Takeaways
- The provided input identifies only the parties and case number (Sanofi-Aventis U.S. LLC v. Breckenridge Pharmaceutical, Inc., 3:15-cv-00289).
- A litigation summary that is accurate and useful for patent estate strength, generic entry timing, and regulatory impact requires docket-specific details (asserted patent numbers, claim outcomes, disposition date, and any settlement terms).
- Those details are not included in the input, so no litigation-specific analysis can be produced under the operating constraints.
FAQs
- What patents were asserted in Sanofi-Aventis v. Breckenridge 3:15-cv-00289?
- What was the court outcome for each asserted patent in 3:15-cv-00289?
- Did the case end in settlement, and what launch terms applied?
- Which ANDA product and strength were at issue in this suit?
- How does the case affect FDA approval and potential generic launch timing?
References
- (No sources provided in the input.)
